About Foresite Capital
Foresite Capital is a venture capital firm founded in 2011. It is primarily based out of New York City, United States. As of Aug 2026, Foresite Capital is an active investor, having invested in 213 companies, with 9 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series D round of Abcuro Overall, Foresite Capital portfolio has seen 7 unicorns, 85 IPOs and 69 acquisitions including key companies like Hims, Natera and 10X Genomics. A lot of funds co-invest with Foresite Capital, with names like Orbimed sharing a substantial percentage of its portfolio. Foresite Capital has team of 27 people including 12 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 7 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Deals in last 12 months
Foresite Capital's List of Top Investments
Foresite Capital has a portfolio of 213 companies, including 7 unicorns. Their most notable investments are in Pinnacle Medicines and Pharvaris.Their portfolio spans across United States, United Kingdom, Canada and 6 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 7 other sectors, across stages such as Series B, Series C and 7 more. Here is the list of top investments by Foresite Capital:
1. Hims
Online platform offering telehealth services for men's wellness. The company focuses on men's wellness and care, offering treatment options for hair loss, erectile dysfunction, and more.
Key facts about Hims
- Founded Year: 2017
- Location: San Francisco (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $197M
- Employee Count: 2,028 as on May 31, 2026
- Investors: Foresite Capital, Brentwood Associates and 17 Others
- Latest Funding Round: Post IPO, May 08, 2025, $*****
- Highlight: Public
2. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 5,857 as on Jun 30, 2026
- Investors: Harmony Partners, Bain Capital Life Sciences and 18 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $*****
- Highlight: Public
3. 10X Genomics
Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis. The company develops instruments, consumables, and software that enable researchers to profile up to a million cells, map RNA and proteins in tissues, and support multiomics workflows, with products cited in publications.
Key facts about 10X Genomics
- Founded Year: 2012
- Location: Pleasanton (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $243M
- Employee Count: 2,330 as on Apr 30, 2026
- Investors: Sprout Capital Partners, Meritech and 14 Others
- Latest Funding Round: Series D, Jan 07, 2019, $*****
- Highlight: Public
4. iRhythm Tech
Provider of cloud-based cardiac rhythm monitoring devices. It provides Zio ambulatory ECG monitor a wearable patch designed to gather beat-to-beat heart data for the diagnosis of cardiac arrhythmias. The device stores data in the patch and is emailed to the iRhythm cloud at the end of the monitoring period. myZio iPhone app is an add-on for the Zio Patch for physicians to make a diagnosis.
Key facts about iRhythm Tech
- Founded Year: 2006
- Location: San Francisco (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $98.9M
- Employee Count: 1,853 as on May 31, 2026
- Investors: Foresite Capital, UNC Kenan-Flagler Private Equity and 12 Others
- Latest Funding Round: Series E, May 22, 2014, $*****
- Highlight: Public
5. PacBio
Developer of instrument systems and software for real-time sequencing of single molecules. It develops a single-molecule real-time sequencing platform that utilizes the two proprietary technologies. It also develops sequencing and other analytical software that assists with the refining of sequence processing and reports.
Key facts about PacBio
- Founded Year: 2004
- Location: Menlo Park (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $410M
- Employee Count: 588 as on Jun 30, 2026
- Investors: T. Rowe Price, Foresite Capital and 24 Others
- Latest Funding Round: Post IPO, Feb 10, 2021, $*****
- Highlight: Public
Foresite Capital's Year-on-Year Investment Trends
Foresite Capital has invested in 214 companies over the last 14 years, with an average of 9 new investments annually in the last 10 years. In 2025, it made 9 investments, while as of Aug 2026, it has made 9 investments in this year. Its most recent first time investment was in Stepful and most recent follow-on round was in Abcuro.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 6 | 3 | 9 |
2025 | 5 | 4 | 9 |
2024 | 11 | 7 | 18 |
2023 | 3 | 4 | 7 |
2022 | 6 | 8 | 14 |
2021 | 14 | 10 | 24 |
2020 | 21 | 12 | 33 |
2019 | 8 | 6 | 14 |
2018 | 13 | 3 | 16 |
2017 | 5 | 3 | 8 |
Foresite Capital's Investments by Stage
Foresite Capital has made 40 investments in Series B stage with an average round size of $66.3M, 26 investments in Series C stage with an average round size of $115M and 24 investments in Series A stage with an average round size of $87.9M.Stage of entry | No. of Investments |
|---|---|
Series B | 40 |
Series C | 26 |
Series A | 24 |
Post IPO | 10 |
Series D | 8 |
Others | 9 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Sector
Foresite Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Enterprise Applications and Sustainability Tech. Notably, it has invested in 193 Tech companies, 184 Enterprise (B2B) companies, 32 Software companies and at least 18 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 100 |
High Tech | 25 |
HealthTech | 18 |
Enterprise Applications | 15 |
Sustainability Tech | 7 |
Others | 16 |
Note: We have considered here, only first round of investments
Foresite Capital's Investments by Geography
Foresite Capital has made most investments in United States (105), followed by United Kingdom where it has made 6 investments.Country | No. of Investments |
|---|---|
United States | 105 |
United Kingdom | 6 |
Ireland | 2 |
China | 1 |
Israel | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Foresite Capital's recent investments
Foresite Capital has made 9 investments in 2026 so far. Abcuro and Obsidian Therapeutics are the latest among them.Here are the most recent investments by Foresite Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 07, 2026 | United States | Series D | 5298 | ||
Aug 05, 2026 | United States | Post IPO | 5468 | ||
Jun 08, 2026 | United States | Series C | 1202 | [+6] | |
May 18, 2026 | United States | Post IPO | 8189 | ||
Mar 26, 2026 | - | Series B | 8404 | [+5] |
Unicorns in Foresite Capital's Portfolio
Foresite Capital has 7 unicorns in its portfolio - Join Midi, Thyme Care, Element Biosciences and others. The most recent unicorn in their portfolio is Join Midi. It became a unicorn in 2026.Here is a list of unicorns in Foresite Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
59 | Provider of a virtual care platform focused on female midlife health | 2021 | Los Altos Hills | Series D | nalbw{k | ||
65 | Provider of home nursing care services | 2020 | Nashville | Series D | kzlzhjw | ||
64 | Developer of benchtop DNA sequencer for research applications | 2017 | San Diego | Series E | cgaueql | ||
65 | Provider of molecular diagnostics platform by using CRISPR technology | 2017 | Brisbane | Series D | amoqgim | ||
60 | Provider of home-based diagnostic tests for the detection of various diseases | 2014 | Austin | Funding Raised | kaxxjbf |
IPOs and Publicly Listed companies in Foresite Capital's Portfolio
85 of Foresite Capital's portfolio companies have become public. Latigo Biotherapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 at marketcap of $1.14B and Parabilis Medicines got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $2.33B.Here are Foresite Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 07, 2026 | Feb 14, 2024 | Series A | 2298 | |
Jun 10, 2026 | Mar 01, 2024 | Series E | 8106 | |
May 08, 2026 | Dec 08, 2021 | Series A | 6735 | |
May 01, 2026 | Oct 18, 2024 | Series B | 5075 | |
Feb 05, 2026 | May 05, 2021 | Series A | 1867 |
Acquired companies in Foresite Capital's Portfolio
69 companies from Foresite Capital's portfolio have been acquired. The most recent acquisition was Kira Pharmaceuticals in Jul 2026 by Jasper Therapeutics for $*****.Here are Foresite Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 16, 2026 | Jan 07, 2021 | Series B | 8325 | |
Jun 17, 2026 | Apr 04, 2025 | Series A | 6705 | |
May 03, 2026 | Sep 09, 2024 | Series D | 8238 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 8250 | |
Dec 15, 2025 | Feb 27, 2018 | Series B | 7068 |
Team profile of Foresite Capital
Foresite Capital has a team of 27 members including 12 Partners and 3 Principals located in United States. Foresite Capital's team sits on the board of 2 companies.Here is a list of top team members in Foresite Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | |||
Partner | San Francisco | |||
Partner | Denver | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | San Francisco | - | ||
Partner | New York City | - | ||
Partner | Denver | - | ||
Partner | New York City | - | ||
Partner | - | - | ||
Partner | - | - | - |
Co-investors of Foresite Capital
Over the past 14 years, 912 investors have co-invested in Foresite Capital's portfolio companies. This includes funds and angels.
- Invested before Foresite Capital: HHS, Google Ventures and 364 others have invested in rounds before Foresite Capital. There are 14 companies where HHS has invested before Foresite Capital and 11 companies where Google Ventures has invested before Foresite Capital.
- Top Co-investors of Foresite Capital: 257 investors entered a company along with Foresite Capital. These include investors like Orbimed (19 companies).
- Invested after Foresite Capital: A total of 289 investors have invested in Foresite Capital's portfolio after their investments. Top Investors include Fidelity Investments (8 companies), RA Capital Management (8 companies) and Janus Henderson Investors (8 companies).
Recent News related to Foresite Capital
•
Khartis Therapeutics Raises $50M in Series B FundingFinSMEs•Aug 13, 2026•Nextech Invest, Forge Life Science Partners, Alexandria, Longwood Fund and 1 other
•
Stepful Announces $55M Series C to Scale Its AI-Powered Training Platform Across the Healthcare WorkforceTraining Industry•Jun 08, 2026•Education Impact Fund, Intermountain Healthcare, Stepful, SemperVirens and 5 others
•
Pinnacle raises an $89M series B for its oral peptide programsBioWorld•Mar 26, 2026•Pinnacle Medicines, LAV, Foresite Capital, Logos and 4 others
•
•
•
•
Midi Health Receives $100M Series D RoundMassinvestor•Feb 03, 2026•Join Midi, SemperVirens, Emerson Collective, Advance Venture Partners and 9 others
•
Parabilis gets $305M to conquer 'undruggable' proteins after early successEndpoints•Jan 08, 2026•Parabilis Medicines, Johnson & Johnson, Frazier Life Sciences, Rock Springs Capital and 19 others
•
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesityEndpoints•Dec 16, 2025•Aeovian Pharmaceuticals, Hevolution, Sofinnova Investments, CTI Life Sciences Fund and 7 others
•
